Pharma Bio Serv Inc (QB)【PBSV】株式ニュース

PBSV reports record quarterly revenues; EPS $.06 vs $.05

CHART
http://stockcharts.com/h-sc/ui?s=pbsv

For the quarter ended 4/13, revenues rose 17% to $8.3M, and net income also rose 17% to $1.39M. Cash rose $1.5M sequentially to $8.5M.

Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2013
DORADO, PUERTO RICO--(Marketwired - Jun 14, 2013) - Pharma-Bio Serv.
(OTCQB: PBSV), a global compliance and validation services consulting
solutions provider, announced net revenues for the three and six months
ended April 30, 2013 of $8.3 and $15.9 million, an increase of approximately
$1.2 and $2.5 million, or 17% and 18%, respectively, when compared to the
same periods last year.
The Company reported net income for the three and six months ended April 30,
2013 of approximately $1.4 and $2.4 million, an increase of $0.2 and $0.1
million, respectively, when compared with the same periods last year.
Revenue growth for the three and six months ended April 30, 2013, over the
same period last year, is mainly attributable to increases in the United
States Consulting market and Lab services, respectively, offset by a
decrease in revenues in the Integratek division and other minor revenue
gains from other Company divisions.
Net income growth, when compared to the same period last year, is
attributable mainly to the aggregate increase in overall gross margins,
offset by the increase in selling general and administrative expenses to
support the favorable revenue trend and business development expenses to
diversify our markets, and the effective income tax rates (including Puerto
Rico favorable tax grants) over income before tax.
Selling, general and administrative expenses for the three and six months
ended April 30, 2013 were approximately $1.4 and $2.7 million, respectively,
a net increase in expenses of approximately $0.4 and $0.8 million,
respectively, as compared to the same periods last year. Business
development and operations support expenses in the Puerto Rico and United
States markets were increased to follow the consulting business favorable
revenue trend. In addition, the Company made business development
investments in Spain to diversify its European division market.
"We are very pleased with our continued performance in expanding our U.S.
presence while efficiently managing our costs," said Nélida Plaza,
Acting Chief Executive Officer, Acting President, Secretary and President of
Puerto Rico Operations. "Our growth is a testament to our ability to
continue to expand our US market base and increase our Lab services
business," she continued.
About Pharma-Bio Serv Inc.
Pharma-Bio Serv is a global compliance and validation services consulting
solutions provider, headquartered in Puerto Rico, with operations in the
U.S, Ireland and Spain. Pharma-Bio Serv's core business is FDA and
international agencies regulatory compliance related services with
integrated portfolio services including microbiological and chemical testing
services for clients in the Pharmaceutical, Biotechnology, Chemical, Medical
Device, Cosmetic, Food and Allied Products industries, at its laboratory
testing facility in Puerto Rico. Services also include "Integratek," an
information technology consulting practice and "Pharma Serv Academy" a
division that provides technical and regulatory standards seminars/training
conducted by industry experts. The Company's global team includes more than
275 leading engineering and life science professionals, quality assurance
managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning
of the U.S. federal securities laws, which statements may include
information regarding the plans, intentions, expectations, future financial
performance, or future operating performance of Pharma-Bio Serv.
Forward-looking statements are based on the expectations, estimates, or
projections of management as of the date of this news release. Although
Pharma-Bio Serv's management believes these expectations, estimates, or
projections to be reasonable as of the date of this news release,
forward-looking statements are inherently subject to significant business
risks, economic and competitive uncertainties, or other contingencies, which
could cause its actual results or performance to differ materially from what
may be expressed or implied in the forward-looking statements. Important
factors that could cause Pharma-Bio Serv's actual results or performance to
differ materially from the forward-looking statements include those set
forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on
Form 10-K for the year ended October 31, 2012 and in its other filings with
the Securities and Exchange Commission, which filings are available on
www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update
or revise any forward-looking statements to reflect subsequent events and
circumstances, except to the extent required by applicable law.
Investor Relations Contact:
Scott Gordon
President
CorProminence LLC
scottg@corprominence.com
631 703 4900